Impax Asset Management Group plc purchased a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 100,000 shares of the company’s stock, valued at approximately $8,548,000. Impax Asset Management Group plc owned approximately 0.15% of Mirum Pharmaceuticals at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of MIRM. Janus Henderson Group PLC boosted its stake in Mirum Pharmaceuticals by 14.5% in the first quarter. Janus Henderson Group PLC now owns 6,945,813 shares of the company’s stock worth $641,764,000 after purchasing an additional 880,505 shares in the last quarter. Jupiter Topco LLC bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $691,672,000. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $513,945,000. William Blair Investment Management LLC bought a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $164,453,000. Finally, Rock Springs Capital Management LP increased its stake in shares of Mirum Pharmaceuticals by 6.4% in the first quarter. Rock Springs Capital Management LP now owns 811,294 shares of the company’s stock valued at $74,947,000 after buying an additional 49,000 shares in the last quarter.
Mirum Pharmaceuticals Stock Up 0.6%
NASDAQ:MIRM opened at $92.49 on Thursday. The stock’s fifty day moving average price is $88.34 and its two-hundred day moving average price is $98.26. Mirum Pharmaceuticals, Inc. has a 52-week low of $63.23 and a 52-week high of $130.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 1.98 and a current ratio of 2.07. The company has a market cap of $6.04 billion, a price-to-earnings ratio of -5.98 and a beta of 0.75.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.38). The firm had revenue of $185.72 million during the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative net margin of 134.75% and a negative return on equity of 97.25%. The firm’s quarterly revenue was up 39.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.05 earnings per share. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.
Insider Transactions at Mirum Pharmaceuticals
In other news, Director Laura Brege sold 14,167 shares of the company’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total transaction of $1,334,673.07. Following the transaction, the director owned 15,703 shares of the company’s stock, valued at $1,479,379.63. This represents a 47.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $90.00, for a total value of $1,800,000.00. Following the completion of the transaction, the chief executive officer owned 206,637 shares in the company, valued at approximately $18,597,330. This represents a 8.82% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,825 shares of company stock worth $6,160,873 over the last 90 days. 8.32% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
MIRM has been the subject of a number of research reports. TD Cowen raised their target price on Mirum Pharmaceuticals from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st. UBS Group set a $137.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, August 27th. Citizens Jmp increased their price objective on shares of Mirum Pharmaceuticals from $144.00 to $167.00 and gave the stock a “market outperform” rating in a report on Wednesday, November 4th. Cantor Fitzgerald increased their price objective on shares of Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 4th. Finally, HC Wainwright raised their price objective on shares of Mirum Pharmaceuticals from $200.00 to $202.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $155.56.
Get Our Latest Analysis on Mirum Pharmaceuticals
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Further Reading
- Five stocks we like better than Mirum Pharmaceuticals
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
